drugset / Trial / NCT00135902

Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies

NCT00135902

RandomizedParallel-groupTriple-blindPrevention

Summary

A recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P) found significant effectiveness for 17P in preventing recurrent preterm birth. However, the group who received 17P in this trial still had a high rate of preterm birth. Several reports have shown that dietary supplementation of fish oil, which is rich in Omega-3 fatty acids, reduces the risk of preterm birth. This trial tests whether adding the Omega-3 supplement to 17P therapy has the potential for further reducing the risk of preterm birth in women who have previously had a spontaneous preterm delivery. The trial will compare Omega-3 fatty acid with placebo in women receiving 17P therapy. The hypothesis being tested is: "Among women at high risk for preterm birth receiving weekly injections of 17P, the addition of Omega-3 nutritional supplement will further reduce the rate of preterm birth."

Timeline

Start
2005-02
Primary completion
2007-03
Completion
2008-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omega-3 supplement Unknown 800 mg Oral
Comparator Omega-3 supplement Unknown 1200 mg Oral
Comparator 17-alpha-hydroxyprogesterone caproate Unknown 250 mg Intramuscular

Indications

No indication recorded.